You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameBudesonide
Accession NumberDB01222  (APRD00442)
TypeSmall Molecule
GroupsApproved
DescriptionBudesonide is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. [PubChem] The extended release oral tablet, marketed as Uceris, was FDA approved on January 14, 2013 for the management of ulcerative colitis. Budesonide is provided as a mixture of two epimers (22R and 22S). Interestingly, the 22R form is two times more active than the 22S epimer. The two forms do not interconvert.
Structure
Thumb
Synonyms
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSpray, metered32 ug/1NasalPar Pharmaceutical2014-10-212017-01-10Us
BudesonideCapsule3 mg/1OralPar Pharmaceutical2011-08-18Not applicableUs
BudesonideSpray, metered32 ug/1NasalAstra Zeneca Lp2014-05-132018-02-28Us
CortimentTablet, extended release9 mgOralFerring Pharmaceuticals2016-07-25Not applicableCanada
EntocortCapsule, extended release3 mgOralTillotts Pharma Gmbh1997-01-30Not applicableCanada
Entocort ECCapsule3 mg/1OralAstra Zeneca Lp2001-10-02Not applicableUs
Entocort ECCapsule3 mg/1OralPaddock Laboratories, Inc.2001-10-29Not applicableUs
Entocort ECCapsule3 mg/1OralPrometheus Laboratories2001-10-29Not applicableUs
Entocort ECCapsule3 mg/1OralPhysicians Total Care, Inc.2006-05-22Not applicableUs
Mylan-budesonide AQSpray, metered100 mcgNasalMylan Pharmaceuticals1997-02-12Not applicableCanada
Mylan-budesonide AQSpray, metered64 mcgNasalMylan Pharmaceuticals1999-11-23Not applicableCanada
Pulmicort FlexhalerAerosol, powder90 ug/1Respiratory (inhalation)Rebel Distributors2010-07-30Not applicableUs
Pulmicort FlexhalerAerosol, powder180 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2007-12-28Not applicableUs
Pulmicort FlexhalerAerosol, powder180 ug/1Respiratory (inhalation)Astra Zeneca Lp2007-03-19Not applicableUs
Pulmicort FlexhalerAerosol, powder180 ug/1Respiratory (inhalation)A S Medication Solutions2007-03-19Not applicableUs
Pulmicort FlexhalerAerosol, powder90 ug/1Respiratory (inhalation)Astra Zeneca Lp2007-03-19Not applicableUs
Pulmicort Nebuamp 0.125 mg/mlSuspension0.125 mgRespiratory (inhalation)Astra Zeneca1997-06-16Not applicableCanada
Pulmicort Nebuamp 0.25 mg/mlSuspension0.25 mgRespiratory (inhalation)Astra Zeneca1992-12-31Not applicableCanada
Pulmicort Nebuamp 0.5 mg/mlSuspension0.5 mgRespiratory (inhalation)Astra Zeneca1992-12-31Not applicableCanada
Pulmicort RespulesSuspension.5 mg/2mLRespiratory (inhalation)Physicians Total Care, Inc.2006-06-29Not applicableUs
Pulmicort RespulesSuspension1 mg/2mLRespiratory (inhalation)Astra Zeneca Lp2007-09-17Not applicableUs
Pulmicort RespulesSuspension.25 mg/2mLRespiratory (inhalation)Physicians Total Care, Inc.2007-06-01Not applicableUs
Pulmicort RespulesSuspension.5 mg/2mLRespiratory (inhalation)Cardinal Health2009-11-20Not applicableUs
Pulmicort RespulesSuspension.25 mg/2mLRespiratory (inhalation)Astra Zeneca Lp2000-09-08Not applicableUs
Pulmicort RespulesSuspension.5 mg/2mLRespiratory (inhalation)Astra Zeneca Lp2000-09-08Not applicableUs
Pulmicort Turbuhaler 100 Mcg/doseAerosol, metered; Powder100 mcgRespiratory (inhalation)Astra Zeneca1990-12-31Not applicableCanada
Pulmicort Turbuhaler 200 Mcg/doseAerosol, metered; Powder200 mcgRespiratory (inhalation)Astra Zeneca1990-12-31Not applicableCanada
Pulmicort Turbuhaler 400 Mcg/doseAerosol, metered; Powder400 mcgRespiratory (inhalation)Astra Zeneca1992-12-31Not applicableCanada
Rhinocort AquaSpray, metered64 mcgNasalAstra Zeneca1997-09-17Not applicableCanada
Rhinocort AquaSpray, metered32 ug/1NasalPhysicians Total Care, Inc.2001-08-20Not applicableUs
Rhinocort AquaSpray, metered32 ug/1NasalAstra Zeneca Lp2001-04-022017-06-30Us
Rhinocort Aqua 100mcgAerosol, metered100 mcgNasalAstra Pharma Inc.1993-12-311999-07-29Canada
Rhinocort Turbuhaler 100 Mcg/dosePowder100 mcgNasal; Respiratory (inhalation)Astra Zeneca1993-12-31Not applicableCanada
UcerisAerosol, foam28 mg/1RectalSalix Pharmaceuticals2014-12-01Not applicableUs
UcerisTablet, extended release9 mg/1OralSantarus, Inc..2013-01-14Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2009-02-04Not applicableUs
BudesonideCapsule3 mg/1OralMylan Pharmaceuticals2011-05-16Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Physicians Total Care, Inc.2009-02-04Not applicableUs
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Apotex Corporation2009-03-30Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2009-02-04Not applicableUs
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Sandoz2015-07-24Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Cardinal Health2009-12-15Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Apotex Corporation2009-03-30Not applicableUs
BudesonideInhalant.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2017-01-20Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Sandoz2015-07-24Not applicableUs
BudesonideCapsule3 mg/1OralGolden State Medical Supply2015-07-10Not applicableUs
BudesonideSuspension1 mg/2mLRespiratory (inhalation)Teva2016-03-11Not applicableUs
BudesonideInhalant.25 mg/2mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation2013-10-01Not applicableUs
BudesonideSuspension1 mg/2mLRespiratory (inhalation)Sandoz2015-07-24Not applicableUs
BudesonideCapsule3 mg/1OralCarilion Materials Management2013-08-23Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2016-11-03Not applicableUs
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Teva2008-11-19Not applicableUs
BudesonideInhalant.5 mg/2mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation2013-10-01Not applicableUs
BudesonideCapsule3 mg/1OralMylan Institutional2011-09-02Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Dispensing Solutions, Inc.2008-11-19Not applicableUs
BudesonideSuspension.5 mg/2mLRespiratory (inhalation)Teva2008-11-19Not applicableUs
BudesonideSuspension.25 mg/2mLRespiratory (inhalation)Physicians Total Care, Inc.2010-01-19Not applicableUs
Budesonide (enteric Coated)Capsule, delayed release pellets3 mg/1OralTeva2016-06-23Not applicableUs
Budesonide (enteric Coated)Capsule, delayed release pellets3 mg/1OralMayne Pharma2016-10-25Not applicableUs
Budesonide (enteric Coated)Capsule3 mg/1OralAlvogen, Inc.2016-11-28Not applicableUs
Budesonide InhalationSuspension.25 mg/2mLRespiratory (inhalation)Impax Generics2016-08-04Not applicableUs
Budesonide InhalationSuspension.5 mg/2mLRespiratory (inhalation)Watson Pharmaceuticals2013-04-02Not applicableUs
Budesonide InhalationSuspension.5 mg/2mLRespiratory (inhalation)Impax Generics2016-08-04Not applicableUs
Budesonide InhalationSuspension.5 mg/2mLRespiratory (inhalation)Preferreed Pharmaceuticals Inc.2015-08-17Not applicableUs
Budesonide InhalationSuspension.25 mg/2mLRespiratory (inhalation)Watson Pharmaceuticals2013-04-02Not applicableUs
Budesonide NasalSpray, metered32 ug/1NasalApotex Corporation2014-05-12Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BudesonideSpray, metered32 ug/1NasalAmerisource Bergen2016-09-15Not applicableUs
BudesonideSpray, metered32 ug/1NasalApotex Corporation2016-04-19Not applicableUs
BudesonideSpray, metered32 ug/1NasalCvs Health2016-04-09Not applicableUs
BudesonideSpray, metered32 ug/1NasalRugby2016-07-13Not applicableUs
BudesonideSpray, metered32 ug/1NasalRite Aid2016-07-13Not applicableUs
BudesonideSpray, metered32 ug/1NasalWalmart2016-08-22Not applicableUs
BudesonideSpray, metered32 ug/1NasalSafeway2016-09-15Not applicableUs
BudesonideSpray, metered32 ug/1NasalTopco Associates2016-08-31Not applicableUs
BudesonideSpray, metered32 ug/1NasalWalgreens2016-04-11Not applicableUs
Childrens Rhinocort AllergySpray, metered32 ug/1NasalJohnson & Johnson Consumer Inc., Mc Neil Consumer Healthcare Division2017-01-16Not applicableUs
Rhinocort AllergySpray, metered32 ug/1NasalJohnson & Johnson Consumer Inc., Mc Neil Consumer Healthcare Division2016-01-14Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
BidienNot Available
BudesonNot Available
BudicortNot Available
ENTOCORTNot Available
NoexEurofarma
PulmicortAstraZeneca
RhinocortAstraZeneca
RhinosolNot Available
SpirocortNot Available
Brand mixtures
NameLabellerIngredients
Entocort EnemaTillotts Pharma Gmbh
SymbicortRemedy Repack
Symbicort 100 TurbuhalerAstra Zeneca
Symbicort 200 TurbuhalerAstra Zeneca
Symbicort Forte TurbuhalerAstra Zeneca
Categories
UNIIQ3OKS62Q6X
CAS number51333-22-3
WeightAverage: 430.5339
Monoisotopic: 430.23553882
Chemical FormulaC25H34O6
InChI KeyVOVIALXJUBGFJZ-KWVAZRHASA-N
InChI
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
IUPAC Name
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosa-14,17-dien-16-one
SMILES
[H][C@@]12C[[email protected]]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Pharmacology
IndicationThe oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.
Structured Indications
PharmacodynamicsBudesonide has a high glucocorticoid effect and a weak mineralocorticoid effect. It binds to the glucocorticoid receptor with a higher binding affinity than cortisol and prednisolone. When budesonide is systemically administered, suppression of endogenous cortisol concentrations and an impairment of the hypothalamus-pituitary-adrenal (HPA) axis function has been observed. Furthermore, a decrease in airway reactivity to histamine and other entities has been observed with the inhaled formulation. Generally, the inhaled formulation has a rapid onset action and improvement in asthma control can occur within 24 hours of initiation of treatment.
Mechanism of actionBudesonide is an anti-inflammatory corticosteroid that exhibits potent glucocorticoid activity and weak mineralocorticoid activity. The precise mechanism of corticosteroid actions on inflammation in asthma, Crohn's disease, or ulcerative colitis is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (eg, mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (eg, histamine, eicosanoids, leukotrienes, and cytokines) involved in allergic and non-allergic-mediated inflammation. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in the aforementioned diseases. Because budesonide undergoes significant first-pass elimination, the both oral preparations are formulated as an extended release tablet. As a result, budesonide release is delyaed until exposure to a pH ≥ 7 in the small intestine.
TargetKindPharmacological actionActionsOrganismUniProt ID
Glucocorticoid receptorProteinyes
antagonist
HumanP04150 details
Related Articles
AbsorptionAbsorption is complete following oral administration. The pharmacokinetic parameters of the inhaled powder formulation are as follows: Tmax = 30 minutes; Absolute systemic availability = 39%. When a single oral administration of 9 mg of Uceris are given, the pharmacokinetic parameters are as follows: Tmax = 13.3 ± 5.9 hours; Cmax = 1.35 ± 0.96 ng/mL; AUC = 16.43 ± 10.52 ng·hr/mL. It is important to note that the parameters have a high degree of variability. When a single oral administration of Entocort EC are given, the pharmacokinetic parameters are as follows: Tmax = 3- 600 minutes; Cmax = 5 nmol/L; AUC = 30 nmol•hr/L.
Volume of distribution

Tablet and capsule, healthy subjects and patients = 2.2 – 3.9 L/kg;
Powder, metered = 3 L/kg

Protein binding85-90% protein bound.
Metabolism

Following absorption, budesonide is subject to high first pass metabolism (80-90%). Budesonide is rapidly and extensively biotransformed, mainly by CYP3A4, to its 2 major metabolites, 6b-hydroxybudesonide and 16a- hydroxyprednisolone. The glucocorticoid activity of these metabolites is negligible (<1/100) in relation to that of the parent compound.

SubstrateEnzymesProduct
Budesonide
16-alpha-hydroxyprednisoloneDetails
Budesonide
6-beta-hydroxybudesonideDetails
Route of eliminationBudesonide is excreted in urine and feces in the form of metabolites. Approximately 60% of an intravenous radiolabelled dose was recovered in the urine. No unchanged budesonide was detected in the urine.
Half lifeFollowing IV administration of budesonide, the elimination half-life is 2.0 to 3.6 hours. This value does not differ between healthy adults and patients with Crohn’s disease.
Clearance

Plasma clearance, tablet = 0.9 – 1.8 L/min;
Systemic clearance, powder, 22R = 1.4 L/min;
Systemic clearance, powder, 22S = 1.0 L/min;
0.5 L/min [Athmatic children 4 to 6 years of age]

ToxicitySingle oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
T-box transcription factor TBX21---(C;G)CG allele (heterozygotes) Effect Directly StudiedBetter response to drug treatment (for asthma) than rs2240017(G;G) homozygotes. Details
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Budesonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Budesonide.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Budesonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Budesonide.Approved
AldesleukinBudesonide may decrease the antineoplastic activities of Aldesleukin.Approved
Aluminum hydroxideThe bioavailability of Budesonide can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Budesonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Budesonide.Approved
AmiodaroneThe serum concentration of Budesonide can be increased when it is combined with Amiodarone.Approved, Investigational
AmiodaroneThe metabolism of Budesonide can be decreased when combined with Amiodarone.Approved, Investigational
Amphotericin BBudesonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Budesonide.Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Budesonide.Approved, Investigational
AprepitantThe serum concentration of Budesonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Budesonide can be increased when it is combined with Atazanavir.Approved, Investigational
AtazanavirThe metabolism of Budesonide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Budesonide can be increased when it is combined with Atomoxetine.Approved
AtomoxetineThe metabolism of Budesonide can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Budesonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Budesonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Budesonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Budesonide.Approved, Investigational
BazedoxifeneThe serum concentration of Budesonide can be increased when it is combined with Bazedoxifene.Approved, Investigational
BendroflumethiazideBudesonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Budesonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Budesonide.Approved
BexaroteneThe serum concentration of Budesonide can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Budesonide can be decreased when combined with Bismuth Subcitrate.Approved
BoceprevirThe serum concentration of Budesonide can be increased when it is combined with Boceprevir.Approved
BoceprevirThe metabolism of Budesonide can be decreased when combined with Boceprevir.Approved
BortezomibThe serum concentration of Budesonide can be increased when it is combined with Bortezomib.Approved, Investigational
BortezomibThe metabolism of Budesonide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Budesonide can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Budesonide.Approved
BumetanideBudesonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Budesonide.Approved, Nutraceutical
Calcium carbonateThe bioavailability of Budesonide can be decreased when combined with Calcium carbonate.Approved
CarbamazepineThe metabolism of Budesonide can be increased when combined with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Budesonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Budesonide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Budesonide.Approved, Investigational
CeritinibThe serum concentration of Budesonide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Budesonide.Approved, Vet Approved
ChlorothiazideBudesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Budesonide can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorthalidoneBudesonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Ciprofloxacin.Approved, Investigational
ClarithromycinThe serum concentration of Budesonide can be increased when it is combined with Clarithromycin.Approved
ClarithromycinThe metabolism of Budesonide can be decreased when combined with Clarithromycin.Approved
ClemastineThe serum concentration of Budesonide can be increased when it is combined with Clemastine.Approved
ClemastineThe metabolism of Budesonide can be decreased when combined with Clemastine.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Budesonide.Approved
ClotrimazoleThe serum concentration of Budesonide can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClotrimazoleThe metabolism of Budesonide can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Budesonide can be increased when it is combined with Cobicistat.Approved
CobicistatThe metabolism of Budesonide can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Budesonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Budesonide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Budesonide can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Budesonide.Approved
CrizotinibThe serum concentration of Budesonide can be increased when it is combined with Crizotinib.Approved
CrizotinibThe metabolism of Budesonide can be decreased when combined with Crizotinib.Approved
CyclosporineThe serum concentration of Budesonide can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Budesonide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Budesonide can be decreased when it is combined with Dabrafenib.Approved
DarunavirThe serum concentration of Budesonide can be increased when it is combined with Darunavir.Approved
DarunavirThe metabolism of Budesonide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Budesonide can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Budesonide is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Budesonide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Budesonide can be increased when it is combined with Delavirdine.Approved
DelavirdineThe metabolism of Budesonide can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Budesonide is combined with Demecarium.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Budesonide.Approved
DexamethasoneThe serum concentration of Budesonide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Budesonide.Approved, Vet Approved
DienestrolThe serum concentration of Budesonide can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Budesonide can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Budesonide.Approved
DihydroergotamineThe serum concentration of Budesonide can be increased when it is combined with Dihydroergotamine.Approved
DihydroergotamineThe metabolism of Budesonide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneBudesonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe serum concentration of Budesonide can be increased when it is combined with Diltiazem.Approved
DiltiazemThe metabolism of Budesonide can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Budesonide is combined with Donepezil.Approved
DoxycyclineThe serum concentration of Budesonide can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxycyclineThe metabolism of Budesonide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe serum concentration of Budesonide can be increased when it is combined with Dronedarone.Approved
DronedaroneThe metabolism of Budesonide can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Budesonide.Approved
EchothiophateThe risk or severity of adverse effects can be increased when Budesonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Budesonide is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Budesonide can be decreased when it is combined with Efavirenz.Approved, Investigational
EnoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Budesonide can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Budesonide.Approved
ErythromycinThe serum concentration of Budesonide can be increased when it is combined with Erythromycin.Approved, Vet Approved
ErythromycinThe metabolism of Budesonide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Budesonide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Budesonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Budesonide can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Budesonide can be increased when it is combined with Estrone.Approved
Etacrynic acidBudesonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Budesonide.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Budesonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Budesonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Budesonide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Budesonide.Approved, Investigational
EtravirineThe serum concentration of Budesonide can be decreased when it is combined with Etravirine.Approved
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Budesonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Budesonide.Approved
FingolimodBudesonide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Budesonide.Approved, Withdrawn
FluconazoleThe serum concentration of Budesonide can be increased when it is combined with Fluconazole.Approved
FluconazoleThe metabolism of Budesonide can be decreased when combined with Fluconazole.Approved
FlumequineThe risk or severity of adverse effects can be increased when Budesonide is combined with Flumequine.Withdrawn
FluoxymesteroneBudesonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Budesonide.Approved, Investigational
FluvoxamineThe serum concentration of Budesonide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FluvoxamineThe metabolism of Budesonide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Budesonide can be increased when it is combined with Fosamprenavir.Approved
FosamprenavirThe metabolism of Budesonide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Budesonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Budesonide can be increased when combined with Fosphenytoin.Approved
FurosemideBudesonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Budesonide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Budesonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Budesonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Budesonide is combined with Gallamine Triethiodide.Approved
GatifloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Budesonide can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Budesonide is combined with Ginkgo biloba.Approved, Nutraceutical
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Budesonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Grepafloxacin.Withdrawn
HexestrolThe serum concentration of Budesonide can be increased when it is combined with Hexestrol.Withdrawn
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Budesonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Budesonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Budesonide.Approved, Investigational
HydrochlorothiazideBudesonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideBudesonide may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Budesonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Budesonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Budesonide.Approved
IdelalisibThe serum concentration of Budesonide can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Budesonide can be increased when it is combined with Imatinib.Approved
ImatinibThe metabolism of Budesonide can be decreased when combined with Imatinib.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Budesonide.Approved
IndapamideBudesonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Budesonide can be increased when it is combined with Indinavir.Approved
IndinavirThe metabolism of Budesonide can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Budesonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Budesonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Budesonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Budesonide is combined with INGN 225.Investigational
IsavuconazoniumThe serum concentration of Budesonide can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsavuconazoniumThe metabolism of Budesonide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe risk or severity of adverse effects can be increased when Budesonide is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Budesonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Budesonide.Withdrawn
IsradipineThe serum concentration of Budesonide can be increased when it is combined with Isradipine.Approved
IsradipineThe metabolism of Budesonide can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Budesonide can be increased when it is combined with Itraconazole.Approved, Investigational
ItraconazoleThe metabolism of Budesonide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Budesonide can be increased when it is combined with Ivacaftor.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Budesonide.Experimental
KetoconazoleThe serum concentration of Budesonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoconazoleThe metabolism of Budesonide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Budesonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Budesonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Budesonide is combined with Leflunomide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Levofloxacin.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Lomefloxacin.Approved
LopinavirThe serum concentration of Budesonide can be increased when it is combined with Lopinavir.Approved
LopinavirThe metabolism of Budesonide can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Budesonide.Approved
LovastatinThe serum concentration of Budesonide can be increased when it is combined with Lovastatin.Approved, Investigational
LovastatinThe metabolism of Budesonide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Budesonide is combined with Loxapine.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Budesonide.Approved
LuliconazoleThe serum concentration of Budesonide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Budesonide can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Budesonide.Approved, Investigational
MagaldrateThe bioavailability of Budesonide can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Budesonide can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of Budesonide can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Budesonide can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Budesonide.Approved
Magnesium TrisilicateThe bioavailability of Budesonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Budesonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Budesonide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Budesonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Budesonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Budesonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Budesonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Budesonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Budesonide.Approved
MestranolThe serum concentration of Budesonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Budesonide.Withdrawn
MethallenestrilThe serum concentration of Budesonide can be increased when it is combined with Methallenestril.Experimental
MethyclothiazideBudesonide may increase the hypokalemic activities of Methyclothiazide.Approved
MethyltestosteroneBudesonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneBudesonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Budesonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MifepristoneThe serum concentration of Budesonide can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Budesonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Budesonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Budesonide.Approved
ModafinilThe serum concentration of Budesonide can be decreased when it is combined with Modafinil.Approved, Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Budesonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Budesonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Budesonide.Approved, Investigational
NafcillinThe serum concentration of Budesonide can be decreased when it is combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Budesonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Budesonide is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Budesonide.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.Approved, Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Budesonide.Investigational
NefazodoneThe serum concentration of Budesonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NefazodoneThe metabolism of Budesonide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Budesonide can be increased when it is combined with Nelfinavir.Approved
NelfinavirThe metabolism of Budesonide can be decreased when combined with Nelfinavir.Approved
NeostigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Budesonide.Approved
NetupitantThe serum concentration of Budesonide can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Budesonide can be increased when it is combined with Nevirapine.Approved
NevirapineThe metabolism of Budesonide can be increased when combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Budesonide is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Budesonide.Approved
NilotinibThe serum concentration of Budesonide can be increased when it is combined with Nilotinib.Approved, Investigational
NilotinibThe metabolism of Budesonide can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Budesonide.Approved, Withdrawn
NorfloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Ofloxacin.Approved
OlaparibThe serum concentration of Budesonide can be increased when it is combined with Olaparib.Approved
OlaparibThe metabolism of Budesonide can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Budesonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Budesonide.Approved
OsimertinibThe serum concentration of Budesonide can be increased when it is combined with Osimertinib.Approved
OxandroloneBudesonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Budesonide.Approved
OxymetholoneBudesonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Budesonide.Withdrawn
PalbociclibThe serum concentration of Budesonide can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Budesonide.Approved
PefloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Pefloxacin.Approved
PentobarbitalThe metabolism of Budesonide can be increased when combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe metabolism of Budesonide can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Budesonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Budesonide.Approved, Vet Approved
PhenytoinThe metabolism of Budesonide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Budesonide.Approved, Investigational
PiretanideBudesonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Budesonide.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Budesonide.Approved, Investigational
PolythiazideBudesonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Budesonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PosaconazoleThe metabolism of Budesonide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Budesonide can be increased when combined with Primidone.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Budesonide.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Budesonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Budesonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneBudesonide may increase the hypokalemic activities of Quinethazone.Approved
RanolazineThe serum concentration of Budesonide can be increased when it is combined with Ranolazine.Approved, Investigational
RanolazineThe metabolism of Budesonide can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Budesonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Budesonide.Experimental, Investigational
RifabutinThe metabolism of Budesonide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Budesonide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Budesonide can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Budesonide is combined with CDX-110.Investigational
RitonavirThe serum concentration of Budesonide can be increased when it is combined with Ritonavir.Approved, Investigational
RitonavirThe metabolism of Budesonide can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Budesonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Budesonide.Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Budesonide.Approved
RosoxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Budesonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Budesonide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Budesonide.Approved
SaquinavirThe serum concentration of Budesonide can be increased when it is combined with Saquinavir.Approved, Investigational
SaquinavirThe metabolism of Budesonide can be decreased when combined with Saquinavir.Approved, Investigational
SildenafilThe serum concentration of Budesonide can be increased when it is combined with Sildenafil.Approved, Investigational
SildenafilThe metabolism of Budesonide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Budesonide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Budesonide can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Budesonide.Approved
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Budesonide.Approved
SparfloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Sparfloxacin.Approved
SRP 299The risk or severity of adverse effects can be increased when Budesonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Budesonide.Investigational
St. John's WortThe serum concentration of Budesonide can be decreased when it is combined with St. John&#39;s Wort.Nutraceutical
StanozololBudesonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Budesonide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Budesonide.Approved
SulfisoxazoleThe serum concentration of Budesonide can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulfisoxazoleThe metabolism of Budesonide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Budesonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Budesonide.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Budesonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Budesonide is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Budesonide.Approved, Investigational
TelaprevirThe serum concentration of Budesonide can be increased when it is combined with Telaprevir.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Budesonide.Approved
TelithromycinThe serum concentration of Budesonide can be increased when it is combined with Telithromycin.Approved
TelithromycinThe metabolism of Budesonide can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Temafloxacin.Withdrawn
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Budesonide.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Budesonide.Approved
TestosteroneBudesonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Budesonide.Approved
TiboloneThe serum concentration of Budesonide can be increased when it is combined with Tibolone.Approved
TiclopidineThe serum concentration of Budesonide can be increased when it is combined with Ticlopidine.Approved
TiclopidineThe metabolism of Budesonide can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Budesonide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibBudesonide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Budesonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Budesonide.Approved
TorasemideBudesonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Budesonide.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Budesonide.Approved, Investigational
TrichlormethiazideBudesonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Budesonide.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Budesonide is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Budesonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Budesonide.Investigational, Withdrawn
VenlafaxineThe serum concentration of Budesonide can be increased when it is combined with Venlafaxine.Approved
VenlafaxineThe metabolism of Budesonide can be decreased when combined with Venlafaxine.Approved
VerapamilThe serum concentration of Budesonide can be increased when it is combined with Verapamil.Approved
VerapamilThe metabolism of Budesonide can be decreased when combined with Verapamil.Approved
VoriconazoleThe serum concentration of Budesonide can be increased when it is combined with Voriconazole.Approved, Investigational
VoriconazoleThe metabolism of Budesonide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinBudesonide may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Budesonide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Budesonide.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Budesonide can be increased when it is combined with Ziprasidone.Approved
ZiprasidoneThe metabolism of Budesonide can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Budesonide.Withdrawn
Food Interactions
  • A mean delay in time to peak concentration of 2.5 hours is observed with the intake of a high-fat meal, with no significant differences in AUC.
References
Synthesis Reference

Peter Gruber, Hans Joachim Lach, Norbert Otterbeck, “Budesonide pellets with a controlled released pattern and process for producing the same.” U.S. Patent US5932249, issued May, 1991.

US5932249
General ReferencesNot Available
External Links
ATC CodesR03AK07A07EA06R03BA02R03AK12D07AC09R01AD05
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (52.3 KB)
MSDSDownload (73.7 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceAsthma1
1CompletedPreventionAcute Chest Syndrome / Asthma / Sickle Cells Disease1
1CompletedTreatmentAllergies1
1CompletedTreatmentAsthma6
1CompletedTreatmentAsthma / Chronic Obstructive Pulmonary Disease (COPD)2
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentSnoring1
1RecruitingTreatmentGraft Versus Host Disease (GVHD) / Transplantation, Stem Cell1
1Unknown StatusTreatmentLiver Cirrhosis, Biliary / Sclerosing Cholangitis1
1, 2CompletedTreatmentAsthma1
1, 2RecruitingPreventionBronchopulmonary Dysplasia (BPD)1
2CompletedNot AvailableAsthma1
2CompletedPreventionAcute Respiratory Distress Syndrome (ARDS)1
2CompletedPreventionLung Cancers2
2CompletedTreatmentAllergic Rhinitis (AR)1
2CompletedTreatmentAllogeneic Stem Cell Transplantation / Bronchiolitis Obliterans1
2CompletedTreatmentAsthma4
2CompletedTreatmentAsthma, Exercise Induced1
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)4
2CompletedTreatmentCopd Bronchitis1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentEosinophilic Esophagitis3
2CompletedTreatmentEosinophilic Esophagitis (EoE)1
2CompletedTreatmentIgA Nephropathy1
2CompletedTreatmentMalignant Melanoma1
2CompletedTreatmentObstructive Airway Disease1
2CompletedTreatmentSeasonal Allergic Rhinitis3
2CompletedTreatmentStable Asthma1
2Not Yet RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentAsthma1
2RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
2RecruitingTreatmentDiarrhea1
2RecruitingTreatmentEarly Stage HER2+ Breast Cancer1
2RecruitingTreatmentEosinophilic Esophagitis1
2RecruitingTreatmentEsophageal Stricture1
2RecruitingTreatmentUlcerative Colitis (UC)1
2SuspendedPreventionBronchiolitis Obliterans / Cryptogenic Organizing Pneumonia / Lung Diseases, Interstitial / Respiratory Tract Infections (RTI)1
2TerminatedPreventionRadiation Proctitis1
2TerminatedTreatmentInflammatory Bowel Diseases (IBD) / Ulcerative Colitis (UC)1
2Unknown StatusPreventionBronchopulmonary Dysplasia1
2Unknown StatusTreatmentCrohn's Disease (CD)1
2Unknown StatusTreatmentTransient Tachypnea of the Newborn1
2WithdrawnTreatmentAcute Graft Versus Host Disease / Intestinal Graft Versus Host Disease1
2WithdrawnTreatmentOlfaction Disorders / Paranasal Sinus Diseases / Sinusitis1
2, 3CompletedTreatmentAllergies1
2, 3CompletedTreatmentEE / Eosinophilic Esophagitis / GastroEsophageal Reflux Disease / GERD1
2, 3CompletedTreatmentHepatitis, Autoimmune1
2, 3CompletedTreatmentPolyps, Nasal1
2, 3CompletedTreatmentSinusitis1
2, 3CompletedTreatmentStatus Asthmaticus1
2, 3TerminatedTreatmentDiarrhea / Lymphocytic Colitis1
3CompletedNot AvailableAsthma1
3CompletedPreventionBronchopulmonary Dysplasia1
3CompletedPreventionGraft Versus Host Disease (GVHD) / Leukemias1
3CompletedPreventionOther and unspecified effects of high altitude1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAsthma43
3CompletedTreatmentAsthma / Chronic Lung Diseases1
3CompletedTreatmentCOPD Patients1
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)5
3CompletedTreatmentCollagenous Colitis2
3CompletedTreatmentCrohn's Disease (CD)4
3CompletedTreatmentEosinophilic Esophagitis1
3CompletedTreatmentGraft Versus Host Disease (GVHD)1
3CompletedTreatmentInduction and Maintaining Remission of Collagenous Colitis1
3CompletedTreatmentMicroscopic Colitis1
3CompletedTreatmentMild or Moderate Asthma1
3CompletedTreatmentOral Chronic Graft vs Host Disease1
3CompletedTreatmentProctitis / Proctosigmoiditis2
3CompletedTreatmentPulmonary Disease, Chronic Obstructive1
3CompletedTreatmentSeasonal Allergic Rhinitis1
3CompletedTreatmentUlcerative Colitis (UC)4
3Not Yet RecruitingTreatmentAsthma1
3Not Yet RecruitingTreatmentAsthma / Bioequivalence1
3Not Yet RecruitingTreatmentRhinitis, Allergic, Perennial2
3RecruitingTreatmentAcute bacterial rhinosinusitis1
3RecruitingTreatmentAcute bacterial rhinosinusitis / Chronic Polyposis1
3RecruitingTreatmentAsthma1
3RecruitingTreatmentBronchial Asthma1
3RecruitingTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3RecruitingTreatmentChronic Obstructive Pulmonary Disorder2
3RecruitingTreatmentChronic Rhinosinusitis With Nasal Polyps1
3RecruitingTreatmentEosinophilic Esophagitis (EoE)1
3RecruitingTreatmentLymphocytic Colitis1
3TerminatedTreatmentPrimary Biliary Cirrhosis (PBC)1
3Unknown StatusTreatmentBronchial Asthma1
3Unknown StatusTreatmentChronic / Polyposis / Sinusitis1
3Unknown StatusTreatmentCollagenous Colitis1
3Unknown StatusTreatmentEmphysema / Poor Sleeping Quality1
3WithdrawnPreventionAltitude Sickness1
4CompletedNot AvailableAsthma1
4CompletedBasic ScienceChronic Obstructive Lung Disease (COLD)1
4CompletedBasic ScienceMild Asthma1
4CompletedSupportive CareAsthma1
4CompletedTreatmentAcute Asthma / Asthma / Reactive Airway Exacerbation1
4CompletedTreatmentAllergic Rhinitis (AR)1
4CompletedTreatmentAsthma12
4CompletedTreatmentBronchial Asthma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)10
4CompletedTreatmentCrohn's Disease (CD)1
4CompletedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)2
4CompletedTreatmentPulmonary Disease, Chronic Obstructive1
4Not Yet RecruitingPreventionChronic Obstructive Pulmonary Disease (COPD) / Lung Cancers / Post Operative Complication, Pulmonary1
4Not Yet RecruitingTreatmentAsthma1
4RecruitingNot AvailableAsthma2
4RecruitingTreatmentAcute bacterial rhinosinusitis / Allergic Rhinosinusitis / Chronic Eosinophilic Rhinosinusitis1
4RecruitingTreatmentAsthma1
4RecruitingTreatmentBronchial Asthma1
4RecruitingTreatmentBronchiectasis / Chronic Obstructive Pulmonary Disease (COPD)1
4RecruitingTreatmentHyposmia1
4RecruitingTreatmentPulmonary Disease,Chronic Obstructive1
4RecruitingTreatmentSevere IgE-mediated Asthma1
4TerminatedTreatmentAsthma1
4TerminatedTreatmentAsthma, Exercise Induced1
4TerminatedTreatmentChronic Obstructive Lung Disease (COLD)1
4TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusPreventionChronic Lung Disease of Prematurity / Respiratory Distress Syndrome (RDS)1
4Unknown StatusTreatmentAsthma1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4Unknown StatusTreatmentEosinophilic Esophagitis1
4Unknown StatusTreatmentObstructive Sleep Apnea (OSA)1
4WithdrawnNot AvailableOsteoporosis1
4WithdrawnBasic ScienceAsthma1
4WithdrawnTreatmentAsthma2
Not AvailableActive Not RecruitingTreatmentAsthma1
Not AvailableCompletedNot AvailableAsthma3
Not AvailableCompletedNot AvailableAsthma / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedNot AvailablePerception of Physicians & Patients of AMD1
Not AvailableCompletedBasic ScienceAsthma2
Not AvailableCompletedDiagnosticAsthma1
Not AvailableCompletedHealth Services ResearchAsthma1
Not AvailableCompletedTreatmentAsthma1
Not AvailableCompletedTreatmentAsthma / Chronic Lung Diseases1
Not AvailableCompletedTreatmentPolyps, Nasal / Sinusitis1
Not AvailableRecruitingNot AvailableCrohn's Disease (CD) / IBD1
Not AvailableRecruitingNot AvailableUlcerative Colitis (UC)1
Not AvailableRecruitingBasic ScienceAsthma1
Not AvailableRecruitingPreventionAir Pollution / COPD Exacerbation1
Not AvailableRecruitingTreatmentChronic Rhinosinusitis / Nasal Polyposis1
Not AvailableRecruitingTreatmentEosinophilic Esophagitis1
Not AvailableTerminatedTreatmentAsthma1
Not AvailableTerminatedTreatmentChronic Rhinosinusitis1
Not AvailableTerminatedTreatmentColitis1
Not AvailableUnknown StatusNot AvailableAllergic Rhinitis (AR) / Asthma1
Not AvailableUnknown StatusNot AvailableFocus of Study is to Improve Asthma Control Based on Phenotype, NO and Sputum Cell Count1
Not AvailableUnknown StatusPreventionRespiratory Sounds2
Not AvailableUnknown StatusTreatmentAsthma2
Not AvailableUnknown StatusTreatmentRespiratory Distress Syndrome (RDS)1
Not AvailableUnknown StatusTreatmentStridor1
Not AvailableWithdrawnTreatmentHepatitis, Autoimmune / Primary Biliary Cirrhosis (PBC)1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
CapsuleOral3 mg/1
InhalantRespiratory (inhalation).25 mg/2mL
InhalantRespiratory (inhalation).5 mg/2mL
Spray, meteredNasal32 ug/1
SuspensionRespiratory (inhalation)1 mg/2mL
Capsule, delayed release pelletsOral3 mg/1
SuspensionRespiratory (inhalation).25 mg/2mL
SuspensionRespiratory (inhalation).5 mg/2mL
Tablet, extended releaseOral9 mg
Capsule, extended releaseOral3 mg
Enema; kit; tabletRectal
Spray, meteredNasal100 mcg
Aerosol, powderRespiratory (inhalation)180 ug/1
Aerosol, powderRespiratory (inhalation)90 ug/1
SuspensionRespiratory (inhalation)0.125 mg
SuspensionRespiratory (inhalation)0.25 mg
SuspensionRespiratory (inhalation)0.5 mg
Aerosol, metered; powderRespiratory (inhalation)100 mcg
Aerosol, metered; powderRespiratory (inhalation)200 mcg
Aerosol, metered; powderRespiratory (inhalation)400 mcg
Spray, meteredNasal64 mcg
Aerosol, meteredNasal100 mcg
PowderNasal; Respiratory (inhalation)100 mcg
AerosolRespiratory (inhalation)
PowderRespiratory (inhalation)
Aerosol, foamRectal28 mg/1
Tablet, extended releaseOral9 mg/1
Prices
Unit descriptionCostUnit
Budesonide micronized powder346.5USD g
DesOwen Lot w/Cetaphil Cream 0.05% Kit Box255.84USD box
Desowen 0.05% ointment kit217.2USD kit
Desowen 0.05% cream kit212.4USD kit
DesOwen 0.05% Lotion 118ml Bottle183.17USD bottle
Pulmicort Flexhaler 180 mcg/act Aerosol Inhaler163.34USD inhaler
Pulmicort 180 mcg flexhaler157.06USD inhaler
DesOwen 0.05% Lotion 59ml Bottle123.38USD bottle
Pulmicort Flexhaler 90 mcg/act Aerosol Inhaler121.98USD inhaler
Pulmicort 90 mcg flexhaler117.29USD inhaler
Rhinocort Aqua 32 mcg/act 8.6 gm Bottle111.96USD bottle
Rhinocort aqua nasal spray13.93USD g
Entocort EC 3 mg 24 Hour Capsule13.86USD capsule
Entocort ec 3 mg capsule12.22USD capsule
Budesonide 0.5 mg/2ml Suspension 2ml Plastic Container9.73USD plastic
Pulmicort 0.5 mg/2ml Suspension 2ml Plastic Container9.24USD plastic
Budesonide 0.25 mg/2ml Suspension 2ml Plastic Container9.07USD plastic
Entocort (115 Ml) 2.3 mg/enm Enema8.93USD enema
Pulmicort 1 mg/2 ml respule8.89USD ml
Pulmicort 0.25 mg/2ml Suspension 2ml Plastic Container7.85USD plastic
Pulmicort 0.5 mg/2 ml respule4.45USD ml
Pulmicort 0.25 mg/2 ml respul3.78USD ml
Desowen 0.05% cream2.43USD g
Pulmicort Nebuamp 0.5 mg/ml Suspension0.93USD ml
Pulmicort Turbuhaler 400 mcg/dose Metered Inhalation Powder0.62USD dose
Pulmicort Nebuamp 0.25 mg/ml Suspension0.46USD ml
Pulmicort Turbuhaler 200 mcg/dose Metered Inhalation Powder0.34USD dose
Pulmicort Nebuamp 0.125 mg/ml Suspension0.23USD ml
Pulmicort Turbuhaler 100 mcg/dose Metered Inhalation Powder0.17USD dose
Rhinocort Turbuhaler 100 mcg/dose Metered Dose Aerosol0.13USD dose
Mylan-Budesonide Aq 100 mcg/dose Metered Dose Spray0.1USD dose
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2071518 No2002-11-122010-11-15Canada
US5914122 No1995-12-192015-12-19Us
US6027714 No1998-01-092018-01-09Us
US6123924 No1997-09-262017-09-26Us
US6142145 No1998-05-082018-05-08Us
US6287540 No1998-01-092018-01-09Us
US6423340 No1993-11-152010-11-15Us
US6598603 Yes1999-06-232019-06-23Us
US6899099 Yes1999-06-232019-06-23Us
US7143764 No1998-03-132018-03-13Us
US7367333 No1998-11-112018-11-11Us
US7410651 No2000-06-092020-06-09Us
US7431943 No2000-06-092020-06-09Us
US7524834 Yes1999-05-112019-05-11Us
US7587988 No2006-04-102026-04-10Us
US7759328 No2003-01-292023-01-29Us
US7897646 No1998-09-092018-09-09Us
US7967011 No2001-08-112021-08-11Us
US8143239 No2003-01-292023-01-29Us
US8293273 No2000-06-092020-06-09Us
US8387615 No2004-11-102024-11-10Us
US8461211 No1998-09-092018-09-09Us
US8528545 No2008-10-162028-10-16Us
US8575137 No2003-01-292023-01-29Us
US8616196 No2009-04-072029-04-07Us
US8784888 No2000-06-092020-06-09Us
US8875699 No2004-11-102024-11-10Us
US8895064 No2011-09-072031-09-07Us
US9132093 No2011-09-072031-09-07Us
US9192581 No2011-09-072031-09-07Us
US9320716 No2000-06-092020-06-09Us
USRE43799 No2000-06-092020-06-09Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point226°CPhysProp
water solubilityinsolubleNot Available
logP1.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0457 mg/mLALOGPS
logP2.42ALOGPS
logP2.73ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)13.74ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity116.11 m3·mol-1ChemAxon
Polarizability47.11 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9872
Blood Brain Barrier+0.9533
Caco-2 permeable-0.6097
P-glycoprotein substrateSubstrate0.804
P-glycoprotein inhibitor INon-inhibitor0.5881
P-glycoprotein inhibitor IINon-inhibitor0.5911
Renal organic cation transporterNon-inhibitor0.7867
CYP450 2C9 substrateNon-substrate0.8488
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7337
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9075
CYP450 2D6 inhibitorNon-inhibitor0.9441
CYP450 2C19 inhibitorNon-inhibitor0.939
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8886
Ames testNon AMES toxic0.9117
CarcinogenicityNon-carcinogens0.9466
BiodegradationNot ready biodegradable0.9759
Rat acute toxicity2.1601 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9483
hERG inhibition (predictor II)Non-inhibitor0.5627
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • Progestogin-skeleton
  • 21-hydroxysteroid
  • Pregnane-skeleton
  • 20-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • 3-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Delta-1,4-steroid
  • Meta-dioxolane
  • Alpha-hydroxy ketone
  • Cyclic alcohol
  • Ketone
  • Cyclic ketone
  • Secondary alcohol
  • Organoheterocyclic compound
  • Oxacycle
  • Acetal
  • Organooxygen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Carbonyl group
  • Organic oxygen compound
  • Alcohol
  • Primary alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Zhang X, Moilanen E, Kankaanranta H: Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone. Eur J Pharmacol. 2000 Oct 20;406(3):325-32. [PubMed:11040338 ]
  2. Henriksson G, Norlander T, Forsgren J, Stierna P: Effects of topical budesonide treatment on glucocorticoid receptor mRNA down-regulation and cytokine patterns in nasal polyps. Am J Rhinol. 2001 Jan-Feb;15(1):1-8. [PubMed:11258648 ]
  3. Zhang X, Moilanen E, Kankaanranta H: Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. Eur J Pharmacol. 2001 Nov 23;431(3):365-71. [PubMed:11730731 ]
  4. Kompella UB, Bandi N, Ayalasomayajula SP: Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1192-201. [PubMed:12601049 ]
  5. Kunz S, Sandoval R, Carlsson P, Carlstedt-Duke J, Bloom JW, Miesfeld RL: Identification of a novel glucocorticoid receptor mutation in budesonide-resistant human bronchial epithelial cells. Mol Endocrinol. 2003 Dec;17(12):2566-82. Epub 2003 Aug 14. [PubMed:12920235 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Jonsson G, Astrom A, Andersson P: Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995 Jan;23(1):137-42. [PubMed:7720517 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 29, 2017 08:03